<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663767</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-797-222</org_study_id>
    <nct_id>NCT00663767</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 2 study designed to test the ability of investigational study drug
      ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to
      further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled
      in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR).</measure>
    <time_frame>6 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the study drug (versus placebo and celecoxib) in terms of pain relief measurements [including TOTPAR, total pain intensity (TPI) and time to rescue medication].</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Dental Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 1, dose 2</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 1</description>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 1: multiple dose levels</description>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 1: multiple dose levels; dose 2</description>
    <arm_group_label>ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib, COX-2 inhibitor; oral</intervention_name>
    <description>dose 1</description>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>dose 2</description>
    <arm_group_label>ARRY-371797, Placebo</arm_group_label>
    <arm_group_label>Celecoxib, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-371797, p38 inhibitor; oral</intervention_name>
    <description>dose 2</description>
    <arm_group_label>Placebo, ARRY-371797</arm_group_label>
    <arm_group_label>Celecoxib, ARRY-371797</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Scheduled for outpatient oral surgical procedure to remove 3 or more third molars, at
             least 1 of which is mandibular and fully or partially impacted by bone.

          -  Females of childbearing potential must be willing to use an acceptable method of
             contraception within 14 days prior to first dose of study drug until the completion of
             the follow-up procedures.

          -  Body weight &gt;50 kg (110 lbs).

          -  Good health determined by medical history, physical examination, vital signs and
             clinical laboratory results of non-clinical significance.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Evidence or history of clinically significant dermatologic, hematological, renal,
             endocrine (e.g. poorly controlled diabetes), pulmonary, gastrointestinal,
             cardiovascular, hepatic, neurologic, ophthalmologic, or allergic disease (including
             clinically significant drug allergies that could impact the conduct of this study, but
             excluding untreated, asymptomatic, seasonal allergies at time of study drug dosing).

          -  Positive urine drug screen within 28 days prior to first dose of study drug.

          -  Use of prohibited prescription drugs, or grapefruit juice within 7 days of first dose
             of study drug; prohibited medications are defined as nonsteroidal and steroidal
             antiinflammatory drugs, analgesics including opioids (except low dose aspirin for
             myocardial infarction prophylaxis), P450 CYP3A substrates or inhibitors (strong or
             moderate).

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://medicine.iupui.edu/flockhart/table.htm</url>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <disposition_first_submitted>December 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2009</disposition_first_posted>
  <last_update_submitted>November 29, 2011</last_update_submitted>
  <last_update_submitted_qc>November 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

